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SCIENTIFIC REPORT
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Aim: To report the findings in a patient treated by repeated
intravitreal bevacizumab (Avastin) injections, followed by
macular relocation and excision of subfoveal choroidal
neovascular membrane (CNV).
Methods: Histopathological evaluation of the CNV specimen,
including immunohistochemical assessment.
Results: During surgical excision, the CNV seemed to be
avascular and its underlying bed did not bleed.
Histopathological examination revealed that the CNV com-
prised avascular fibrous subretinal tissue containing fibroblastic
retinal pigment epithelial (RPE) cells, fragments of irregular
thickened Bruch’s membrane and fibrotic choroidal tissue
containing some medium-sized vessels but no choriocapillaris.
Conclusions: The development of an RPE tear during the course
of Avastin treatment may reflect contraction of the avascular
subretinal tissue, whereas the lack of capillaries in both
choroidal and subretinal components may be caused by the
increased access of Avastin to the choriocapillaris in the
presence of the RPE tear.
I
n the era of increasing use of antivascular endothelial growth
factor treatment in age-related macular degeneration (AMD),
we demonstrate histopathological correlations of clinical
observations regarding the biological effects of bevacizumab
on a choroidal neovascular membrane (CNV).
PATIENT AND METHODS
A 74-year-old man underwent macular translocation surgery
following repeated intravitreal bevacizumab (Avastin) injec-
tions. The first intervention consisted of pneumatic displace-
ment of subretinal blood, followed by intravitreal bevacizumab
injection in another unit. After a good initial visual response
(20/40), the patient’s vision dropped to 20/125, requiring a
second injection. This was followed by a retinal pigment
epithelial (RPE) tear. A third injection temporarily improved
vision to 20/200, only for it to deteriorate again to 20/320 (26
letters at 2 m). Faced with the imminent loss of vision in his
second eye, the patient chose the surgical option of macular
translocation.
Macular translocation with 360˚retinotomy was performed,
consisting of phacovitrectomy, 360˚ retinotomy and 1300
centistokes silicone oil endotamponade, and excision of the
CNV complex. This complex seemed to be avascular (fig 1) and
the underlying bed hardly bled following excision. The excised
tissue measured 4 mm in diameter. It was fixed in 10% neutral
buffered formalin, dehydrated in ethanol and embedded in
paraffin wax. Histopathological examination revealed that the
CNV complex comprised three distinct components: fibrous
subretinal tissue containing fibroblastic cells, fragments of
irregular thickened Bruch’s membrane and fibrotic choroidal
tissue containing some medium-sized vessels but no chorio-
capillaris (fig 2). Immunohistochemistry using cytokeratin 7
antibodies confirmed that the fibroblastic cells in the subretinal
component were of RPE origin and that a few cells in the
choroidal element were of a similar origin (fig 2).
Immunohistochemistry for the endothelial marker CD34
confirmed the lack of vasculature in the subretinal part of the
CNV (fig 2).
Eighty-six days later, four-muscle-counter-rotation surgery
followed, including silicone oil removal. At 4 months following
removal of silicone oil and muscle relocation surgery, the best-
corrected visual acuity was 20/80.
DISCUSSION
We report the clinical and histopathological findings of a CNV
excised during macular translocation after failure of intravitreal
bevacizumab treatment.
Over-expression of vascular endothelial growth factor
(VEGF) in the RPE has been considered an important factor
in the pathogenesis of choroidal neovascularisation in AMD.1
Bevacizumab is a humanised anti-VEGF monoclonal antibody,
which binds and inhibits all VEGF isoforms. This leads to a
reduction in VEGF-induced cell proliferation and tissue factor
production.
Despite the lack of any phase III clinical trial data, there is an
emerging practice of using bevacizumab for the treatment of
choroidal neovascularisation. Short-term studies suggest that
this is a safe and effective treatment.2 3 However, our patient
developed an RPE tear following the second bevacizumab
injection. Although it has been stated that an RPE tear is not a
frequent complication of the treatment,4 Meyer et al5 recently
described two such cases following intravitreal bevacizumab
injection.
A histopathological examination of the excised specimen
following bevacizumab treatment indicated that it consisted of
largely fibrotic choroid, irregular Bruch’s membrane and an
avascular subretinal RPE proliferation set in fibrous tissue. One
of the most striking observations in the tissue was the lack of
capillaries either in choroid or in the CNV elements. This
finding correlated with the clinical observation that the CNV
was avascular and with the lack of significant haemorrhage
from the underlying bed after excision. However, as the RPE
tear created a window defect with a resultant hyperfluores-
cence in the preoperative fundus fluorescein angiogram (fig 3),
Abbreviations: AMD, age-related macular degeneration; CNV, choroidal
neovascular membrane; RPE, retinal pigment epithelial; VEGF, vascular
endothelial growth factor
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it was difficult to evaluate the status of the choriocapillaris
before surgery.
Absence of capillaries in CNV is not unusual, especially in the
late stages of AMD.6 Equally, it is well recognised that the
choriocapillaris may become partially atrophic in the same
situation.7 However, a total absence of capillaries in both CNV
and choroid is outside our previous experience of excised CNV
complexes, even after photodynamic treatment.8 Thus, the
combined histological and clinical findings raise the possibility
that the avascularity reflects ‘‘withdrawal’’ of VEGF from the
tissue after Avastin treatment. Indeed, it is well recognised that
endothelial channels are highly susceptible to VEGF loss.9
The choroidal changes in our patient seemed to be restricted
to the foveal area. If they were (partly) due to the Avastin
treatment, the localisation to the fovea may be a consequence
of the RPE tear. Such a tear may have permitted access of
Avastin to the underlying choroid.
The histological appearances of the subretinal membrane are
typical of a wound healing response involving RPE cells.10 From
the clinical viewpoint, contraction associated with the wound
healing response of the subretinal membrane may have
contributed to the RPE tear. This possibility may be a concern
for the use of Avastin in AMD presenting with a large
fibrovascular PED.
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Figure 1 Relative avascularity of choroidal neovascular complex during
surgical excision (black arrow). Retina folded nasally (left side).
Figure 2 (A) Periodic acid-Schiff reagent and haematoxylin-stained
section of the excised tissue showing magenta-coloured, irregular,
thickened Bruch’s membrane structure (arrows), discontinuous pigment cell
layer (arrowheads), fibrous subretinal component (S) and fibrous choroidal
remains (C). Inset: H&E staining of the specimen highlights its paucicellular
nature. (B) Labelling with the retinal pigment epithelial (RPE) marker
cytokeratin 7 demonstrates that the cells in the subretinal membrane are of
RPE origin, as are a few in the choroidal scar (arrowheads). (C) Labelling
with the vascular endothelial marker CD34 reveals that the subretinal
component is avascular, whereas the choroid lacks capillaries, contains a
few larger vessels (arrowheads) and is fibrotic. Inset: negative control
section in which the primary antibody was replaced by an irrelevant
antibody.
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Figure 3 Preoperative photographs. (A) Colour fundal photograph. (B)
Early frames of fundal fluorescein angiogram depicting the window defect.
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